Valuation : Delcath Systems, Inc.

Market Cap 558M 480M 451M 412M 769M 52.9B 773M 5.35B 2.07B 27.04B 2.1B 2.05B 86.04B P/E 2026 *
-107x
P/E 2027 * -201x
Enterprise Value 558M 480M 451M 412M 769M 52.9B 773M 5.35B 2.07B 27.04B 2.1B 2.05B 86.04B EV / Sales 2026 *
5.25x
EV / Sales 2027 * 4.23x
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 2020-09-30
Director of Finance/CFO 47 2023-04-30
Chief Operating Officer 55 2024-03-17
Director TitleAgeSince
Chairman 62 2023-02-15
Director/Board Member 70 2020-02-13
Director/Board Member 60 2020-05-05
Change 5-day change 1-year change 3-year change Capi.($)
+1,204.85%+1,166.82% - - 572M
+0.60%-3.90%-1.80%-27.18% 18.34B
-0.34%-1.20%-3.87%+7.43% 17.04B
-2.08%+0.18%-54.26%-48.91% 6.63B
+0.88%-4.01% - - 4.23B
0.00%-2.28%+32.82%+69.00% 2.11B
+0.18%-1.90%-8.23%-6.11% 1.88B
+0.98%-0.52%-51.15%-55.51% 1.15B
-0.51%-4.15%+40.64%+151.14% 926M
-2.43%-1.95%+39.22%+234.30% 572M
Average +120.16%+0.13%-0.83%+40.52% 5.88B
Weighted average by Cap. +12.77%+0.08%-8.29%-7.22%

Financials

2026 *2027 *
Net sales 106M 91.32M 85.91M 78.4M 146M 10.07B 147M 1.02B 394M 5.15B 399M 390M 16.38B 132M 113M 107M 97.43M 182M 12.51B 183M 1.26B 489M 6.4B 496M 485M 20.35B
Net income -5.72M -4.92M -4.63M -4.22M -7.88M -542M -7.92M -54.83M -21.21M -277M -21.48M -21.01M -882M -3.39M -2.91M -2.74M -2.5M -4.67M -321M -4.69M -32.47M -12.56M -164M -12.72M -12.44M -522M
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!